RecruitingPhase 1NCT07090499
Oncology
Squamous cell carcinoma of pancreas
46
studies recruiting now
as of 7 Sept 2026
173
studies registered in total
as of 7 Sept 2026
11
countries with a recruiting site
as of 7 Sept 2026
29 Jul 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT04858334
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
RecruitingPhase 1NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingNCT04981119
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingNot applicableNCT05837767
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 46 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Squamous cell carcinoma of pancreas study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Squamous cell carcinoma of pancreas
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).